Compounds > quinazolines
Page last updated: 2024-08-21

quinazolines and Small Cell Lung Carcinoma

quinazolines has been researched along with Small Cell Lung Carcinoma in 43 studies

Research

Studies (43)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (4.65)29.6817
2010's38 (88.37)24.3611
2020's3 (6.98)2.80

Authors

AuthorsStudies
Chan, YC; Chang, CJ; Chao, JI; Chen, C; Chen, CH; Hsu, YP; Liang, MC; Liu, KK; Pan, PY; Wang, RH; Wang, SP; Wong, KK; Wu, YH; Yang, CM; Yang, JM1
Ali, SM; Chen, G; Chen, J; Chen, S; Chen, Y; Cui, J; Dong, X; Duan, J; Fang, J; Feng, J; Guo, R; Hu, C; Hu, J; Hu, Y; Ji, Y; Jian, H; Jiang, L; Jie, W; Jie, Z; Li, B; Li, C; Li, J; Li, W; Lin, Z; Liu, C; Lu, J; Lu, S; Lu, Y; Lv, D; Ma, L; Ma, R; Miller, VA; Shi, J; Sun, C; Sun, M; Sun, Y; Tong, W; Wang, Q; Wang, Z; Wei, H; Wu, Q; Wu, X; Xiong, J; Xu, X; Xu, Z; Yang, H; Yang, N; Yao, Y; Ye, X; Yu, X; Yu, Z; Zhang, G; Zhang, H; Zhang, L; Zhang, Z; Zhou, J; Zhou, X1
Hu, X; Li, N; Liu, H; Qi, D; Wang, T; Zhang, J; Zhang, X; Zhong, C1
Fan, Y; Gong, L; Huang, Z; Xu, Y1
Bergqvist, M; Bergström, S; Ekman, S; Gullbo, J; Lennartsson, J; Sooman, L1
Boumber, Y; Chaudhary, S; Kesari, K; Khan, H; Khan, M; Smith, S; Wahab, A1
Chai, Y; Wu, Y; Yao, Y; Zhu, Z1
Essenburg, C; Kaufman, D; Lewis, S; Staal, B; Vande Woude, GF; Zhang, YW1
Popat, S; Yap, TA1
Yaqub, F1
Chi, HS; Cho, YU; Jang, S; Kim, SW; Kim, YJ; Park, CJ; Park, SH1
Yano, S1
Berger, MF; Kris, MG; Krug, LM; Ladanyi, M; Pietanza, MC; Rekhtman, N; Riely, GJ; Varghese, AM; Wang, L; Won, HH; Yu, HA; Zakowski, MF1
Adjei, AA; Foster, NR; Grainger, AV; Marks, R; Molina, JR; Nelson, GD; Reungwetwattana, T; Steen, PD; Stella, PJ; Wright, J1
Takeuchi, S; Yano, S1
Fan, X; Fang, C; Liu, L; Luo, J; Qi, D; Tan, Q; Zhang, J1
Abdullaev, Z; Beadling, C; Berman, A; Carter, CA; Corless, CL; Doyle, A; Giaccone, G; Guha, U; Kelly, R; Killian, K; Lau, CC; Liewehr, DJ; Lopez-Chavez, A; Meltzer, PS; Morrow, B; Pack, S; Raffeld, M; Rajan, A; Sandler, A; Steinberg, SM; Szabo, E; Thomas, A; Wang, Y; Warrick, A; Xi, L1
Bernardo, LA; Borger, DR; Costa, C; Costa, DB; Engelman, JA; Fulton, LE; Garcia, AR; Getz, G; Howe, E; Iafrate, AJ; Jänne, PA; Katayama, R; Lockerman, EL; Mermel, CH; Mino-Kenudson, M; Miyoshi, N; Mohamoud, F; Moran, T; Mulvey, HE; Niederst, MJ; Poirier, JT; Ramaswamy, S; Ross, KN; Rudin, CM; Sequist, LV; Shioda, T; VanderLaan, PA1
Dong, X; Li, K; Li, Q; Li, Z; Liu, L; Meng, R; Wu, G; Zhang, S; Zhou, F; Zhou, Y1
Huo, Z; Jiang, SY; Wang, MZ; Xu, Y; Zhang, J; Zhao, J; Zhong, W1
Bunn, PA; Chan, DC; Gao, D; Helfrich, BA; Kim, J; Tan, AC; Zhang, Z1
Guarino, M; Hanna, N; Jayaram, N; Masters, GA; Misleh, J; Patel, JD; Sanborn, RE; Stephens, A; Wu, J1
Ellison, K; Hirsch, FR; Kim, J; Mitsudomi, T; Murakami, I; Rivard, CJ; Suda, K; Yu, H1
Becker, M; Fichtner, I; Hammer, S; Hoffmann, J; Merk, J; Rolff, J; Sommer, A; Soong, R1
Bryce, J; De Feo, G; De Maio, E; Del Giudice, A; Di Maio, M; Falasconi, F; Morabito, A; Normanno, N; Perrone, F; Piccirillo, MC1
Eck, MJ; Yun, CH1
Besse, B; Soria, JC; Vignot, S1
Belani, CP; Gandara, DR; Govindan, R; Ivy, SP; Koczywas, M; Longmate, J; Mack, PC; Ramalingam, SS; Vokes, EE1
Bago-Horvath, Z; Berger, W; Cejka, D; Filipits, M; Haitel, A; Hayden, H; Herberger, B; Schmid, K; Sieghart, W; Werzowa, J1
Fujita, J; Furuta, J; Hizawa, N; Kikuchi, N; Miyazaki, K; Morishima, Y; Nozato, K; Ogawa, R; Sakamoto, T1
Alauddin, MM; Balatoni, JA; Gelovani, JG; Gonzalez-Lepera, C; Mukhopadhyay, U; Ogawa, K; Pal, A; Shavrin, A; Tong, W; Volgin, A1
Lee, P1
Camidge, DR; Cappuzzo, F; Varella-Garcia, M1
Chin, A; Depinho, RA; Dinulescu, DM; Faça, VM; Gazdar, AF; Goodman, G; Hanash, SM; Kelly-Spratt, K; Kemp, CJ; Kucherlapati, R; Lockwood, WW; Park, KS; Pitteri, SJ; Politi, K; Sage, J; Taguchi, A; Varmus, HE; Wong, CH; Zhang, Q1
Chan, WK; Cheng, PN; Cheng, T; Ma, AT; Ma, ES1
Aftab, D; Chen, X; Chmielecki, J; Hutchinson, K; Kris, MG; Miller, V; Pao, W; Pietanza, MC; Rizvi, N; Shen, R; Stout, T; Viale, A; Zhao, Z1
Damse, A; Lacouture, ME; Rosen, AC; Sherman, E; Wu, S1
Hirata, H; Inoue, K; Kida, H; Kijima, T; Kohmo, S; Kumanogoh, A; Minami, T; Nagatomo, I; Otani, Y; Suzuki, M; Tachibana, I; Takahashi, R; Takeda, Y1
Antoine, M; Belmont, L; Cadranel, J; Fallet, V; Lacave, R; Lavolé, A; Poulot, V; Ruppert, AM; Wislez, M1
Biesma, B; Heideman, D; Smit, EF; Thunnissen, E; van Riel, S1
Gonzalez, D; Nicholson, AG; Nutting, CM; O'Brien, M; Popat, S; Wotherspoon, A1
Chung, DH; Heo, DS; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Kim, YT; Kim, YW; Lee, SH; Park, JH1
Banna, GL; Bellavia, M; Borsellino, N; Ferraù, F; Gebbia, V; Russo, P; Tralongo, P1

Reviews

7 review(s) available for quinazolines and Small Cell Lung Carcinoma

ArticleYear
The role of afatinib in the management of non-small cell lung carcinoma.
    Expert opinion on drug metabolism & toxicology, 2013, Volume: 9, Issue:11

    Topics: Afatinib; Antineoplastic Agents; Cell Line, Tumor; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Drug Resistance, Neoplasm; Humans; Lung Neoplasms; Protein-Tyrosine Kinases; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma

2013
[Programs for continuing medical education: B session; 4. Progress in lung cancer therapy].
    Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, 2014, Mar-10, Volume: 103, Issue:3

    Topics: Anaplastic Lymphoma Kinase; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Camptothecin; Cisplatin; Crizotinib; Drug Discovery; Education, Medical, Continuing; Erlotinib Hydrochloride; Etoposide; Gefitinib; Glutamates; Guanine; Humans; Irinotecan; Lung Neoplasms; Molecular Targeted Therapy; Pemetrexed; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Quinazolines; Receptor Protein-Tyrosine Kinases; Small Cell Lung Carcinoma

2014
Clinical significance of epidermal growth factor receptor tyrosine kinase inhibitors: sensitivity and resistance.
    Respiratory investigation, 2014, Volume: 52, Issue:6

    Topics: Antineoplastic Agents; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; Epithelial-Mesenchymal Transition; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Membrane Proteins; Molecular Targeted Therapy; Mutation; Polymorphism, Genetic; Protein Kinase Inhibitors; Proto-Oncogene Proteins; Quinazolines; Small Cell Lung Carcinoma

2014
Small-Cell Lung Cancer Transformation in Patients With Pulmonary Adenocarcinoma: A Case Report and Review of Literature.
    Medicine, 2016, Volume: 95, Issue:6

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Recurrence, Local; Pemetrexed; Platinum; Quinazolines; Small Cell Lung Carcinoma

2016
Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions.
    The oncologist, 2009, Volume: 14, Issue:4

    Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Docetaxel; Drug Therapy; ErbB Receptors; Glutamates; Guanine; Humans; Lung Neoplasms; Pemetrexed; Piperidines; Quinazolines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Small Cell Lung Carcinoma; Taxoids; Treatment Outcome; Vascular Endothelial Growth Factor Receptor-1

2009
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer.
    Biochimica et biophysica acta, 2010, Volume: 1804, Issue:3

    Topics: Animals; Catalytic Domain; Drug Resistance, Neoplasm; Enzyme Activation; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Quinazolines; Small Cell Lung Carcinoma; Structure-Activity Relationship

2010
Risk of rash in cancer patients treated with vandetanib: systematic review and meta-analysis.
    The Journal of clinical endocrinology and metabolism, 2012, Volume: 97, Issue:4

    Topics: Antineoplastic Agents; Breast Neoplasms; Carcinoma, Neuroendocrine; Carcinoma, Non-Small-Cell Lung; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Eruptions; ErbB Receptors; Female; Humans; Incidence; Lung Neoplasms; Male; Piperidines; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-ret; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Risk; Severity of Illness Index; Small Cell Lung Carcinoma; Thyroid Neoplasms

2012

Trials

5 trial(s) available for quinazolines and Small Cell Lung Carcinoma

ArticleYear
AENEAS: A Randomized Phase III Trial of Aumolertinib Versus Gefitinib as First-Line Therapy for Locally Advanced or MetastaticNon-Small-Cell Lung Cancer With
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2022, 09-20, Volume: 40, Issue:27

    Topics: Acrylamides; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Exons; Gefitinib; Humans; Indoles; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Small Cell Lung Carcinoma

2022
A phase II trial of the Src-kinase inhibitor saracatinib after four cycles of chemotherapy for patients with extensive stage small cell lung cancer: NCCTG trial N-0621.
    Lung cancer (Amsterdam, Netherlands), 2014, Volume: 85, Issue:2

    Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzodioxoles; Disease Progression; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Protein Kinase Inhibitors; Quinazolines; Retreatment; Small Cell Lung Carcinoma; src-Family Kinases; Treatment Outcome

2014
Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2015, Mar-20, Volume: 33, Issue:9

    Topics: Adolescent; Adult; Aged; Benzimidazoles; Biomarkers, Tumor; Carcinoma, Non-Small-Cell Lung; Class I Phosphatidylinositol 3-Kinases; ErbB Receptors; Erlotinib Hydrochloride; Female; Genes, ras; Humans; Indoles; Lapatinib; Lung Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Mutation; Phosphatidylinositol 3-Kinases; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; PTEN Phosphohydrolase; Pyrroles; Quinazolines; ras Proteins; Reproducibility of Results; Small Cell Lung Carcinoma; Sunitinib; Thymus Neoplasms; Treatment Outcome; Young Adult

2015
A randomized, double-blind, phase 2 trial of platinum therapy plus etoposide with or without concurrent vandetanib (ZD6474) in patients with previously untreated extensive-stage small cell lung cancer: Hoosier Cancer Research Network LUN06-113.
    Cancer, 2017, 01-01, Volume: 123, Issue:2

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Cisplatin; Disease Progression; Double-Blind Method; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Organoplatinum Compounds; Piperidines; Quinazolines; Small Cell Lung Carcinoma

2017
Phase II study of Cediranib (AZD 2171), an inhibitor of the vascular endothelial growth factor receptor, for second-line therapy of small cell lung cancer (National Cancer Institute #7097).
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010, Volume: 5, Issue:8

    Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Resistance, Neoplasm; Female; Humans; Lung Neoplasms; Male; Middle Aged; National Cancer Institute (U.S.); Neoplasm Recurrence, Local; Neoplasm Staging; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate; Treatment Outcome; United States

2010

Other Studies

31 other study(ies) available for quinazolines and Small Cell Lung Carcinoma

ArticleYear
A novel EGFR inhibitor suppresses survivin expression and tumor growth in human gefitinib-resistant EGFR-wild type and -T790M non-small cell lung cancer.
    Biochemical pharmacology, 2021, Volume: 193

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Resistance, Neoplasm; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Piperazines; Protein-Tyrosine Kinases; Quinazolines; Small Cell Lung Carcinoma; Survivin; Xenograft Model Antitumor Assays

2021
A novel evodiamine amino derivative as a PI3K/AKT signaling pathway modulator that induces apoptosis in small cell lung cancer cells.
    European journal of pharmacology, 2021, Sep-05, Volume: 906

    Topics: Administration, Oral; Animals; Apoptosis; Cell Line, Tumor; Cell Survival; Drug Screening Assays, Antitumor; Humans; Lung Neoplasms; Male; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins c-akt; Quinazolines; Rats; Signal Transduction; Small Cell Lung Carcinoma

2021
A case of resistance to tyrosine kinase inhibitor therapy: small cell carcinoma transformation concomitant with plasma-genotyped T790M positivity.
    Anti-cancer drugs, 2017, Volume: 28, Issue:9

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cell Transformation, Neoplastic; Cisplatin; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Lung Neoplasms; Mutation; Pemetrexed; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2017
Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.
    BMC research notes, 2017, Nov-02, Volume: 10, Issue:1

    Topics: Adenocarcinoma; Antineoplastic Agents; Bortezomib; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cell Line, Tumor; Cisplatin; Deoxycytidine; Drug Therapy, Combination; Gefitinib; Gemcitabine; Humans; Piperidones; Proteasome Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Vinblastine; Vinorelbine

2017
Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Cancer biology & therapy, 2017, Dec-02, Volume: 18, Issue:12

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aged; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Liver Neoplasms; Lung Neoplasms; Male; Neoplasm Metastasis; Positron Emission Tomography Computed Tomography; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2017
Histologic transformation from adenocarcinoma to both small cell lung cancer and squamous cell carcinoma after treatment with gefitinib: A case report.
    Medicine, 2018, Volume: 97, Issue:18

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Carcinoma, Squamous Cell; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Fatal Outcome; Gefitinib; Humans; Lung Neoplasms; Male; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2018
Strengthening context-dependent anticancer effects on non-small cell lung carcinoma by inhibition of both MET and EGFR.
    Molecular cancer therapeutics, 2013, Volume: 12, Issue:8

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Disease Models, Animal; Drug Synergism; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyridazines; Quinazolines; Signal Transduction; Small Cell Lung Carcinoma; Triazoles; Xenograft Model Antitumor Assays

2013
American Society of Clinical Oncology Annual Meeting 2013.
    The Lancet. Respiratory medicine, 2013, Volume: 1, Issue:5

    Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States

2013
A case of residual non-small cell lung cancer cells coexisting with newly developed small cell lung cancer cells in ascitic fluid after chemotherapy for non-small cell lung cancer.
    Annals of laboratory medicine, 2014, Volume: 34, Issue:2

    Topics: Antineoplastic Agents; Ascitic Fluid; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Staging; Quinazolines; Small Cell Lung Carcinoma; Tomography, X-Ray Computed

2014
Small-cell lung cancers in patients who never smoked cigarettes.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2014, Volume: 9, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Chromogranins; Class I Phosphatidylinositol 3-Kinases; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Amplification; Gene Rearrangement; GTP-Binding Protein alpha Subunits, Gs; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasms, Second Primary; Phosphatidylinositol 3-Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-cbl; Proto-Oncogene Proteins p21(ras); Quinazolines; ras Proteins; Receptor Protein-Tyrosine Kinases; Retinoblastoma Protein; Retrospective Studies; Small Cell Lung Carcinoma; Smoking; Survival Rate; Telomerase; Tumor Suppressor Protein p53

2014
Evodiamine induces G2/M arrest and apoptosis via mitochondrial and endoplasmic reticulum pathways in H446 and H1688 human small-cell lung cancer cells.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Endoplasmic Reticulum; Humans; Lung Neoplasms; M Phase Cell Cycle Checkpoints; Mitochondria; Quinazolines; Small Cell Lung Carcinoma

2014
RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Nature communications, 2015, Mar-11, Volume: 6

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Afatinib; Aniline Compounds; Antineoplastic Agents; bcl-X Protein; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Disease Progression; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Gene Expression Regulation, Neoplastic; Humans; Lung; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-bcl-2; Quinazolines; Recurrence; Retinoblastoma Protein; Signal Transduction; Small Cell Lung Carcinoma; Sulfonamides

2015
Quinalizarin, a specific CK2 inhibitor, reduces cell viability and suppresses migration and accelerates apoptosis in different human lung cancer cell lines.
    Indian journal of cancer, 2015, Volume: 52 Suppl 2

    Topics: Adenocarcinoma; Apoptosis; Carcinoma, Large Cell; Casein Kinase II; Cell Movement; Cell Proliferation; Flow Cytometry; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured

2015
Barasertib (AZD1152), a Small Molecule Aurora B Inhibitor, Inhibits the Growth of SCLC Cell Lines In Vitro and In Vivo.
    Molecular cancer therapeutics, 2016, Volume: 15, Issue:10

    Topics: Animals; Antineoplastic Agents; Aurora Kinase B; Cell Line, Tumor; Cell Proliferation; Cluster Analysis; Disease Models, Animal; Dose-Response Relationship, Drug; Gene Amplification; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Genes, myc; Histones; Humans; Lung Neoplasms; Mice; Organophosphates; Phosphorylation; Polyploidy; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Transcriptome; Tumor Burden; Xenograft Model Antitumor Assays

2016
Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2017, Volume: 12, Issue:6

    Topics: Adenocarcinoma; Aged; Biomarkers; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Liver Neoplasms; Lung Neoplasms; Lymphatic Metastasis; Mutation; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2017
Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Oct-15, Volume: 14, Issue:20

    Topics: Adenocarcinoma; Adult; Aged; Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Biomarkers, Tumor; Carboplatin; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Cetuximab; Deoxycytidine; Disease Models, Animal; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Etoposide; Female; Gemcitabine; Gene Expression Profiling; Genes, ras; Humans; Immunoblotting; Lung Neoplasms; Male; Mice; Mice, Inbred NOD; Mice, Nude; Mice, SCID; Middle Aged; Mutation; Oligonucleotide Array Sequence Analysis; Paclitaxel; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Radiation-Sensitizing Agents; Small Cell Lung Carcinoma; Tumor Suppressor Protein p53; Vinblastine; Vinorelbine; Xenograft Model Antitumor Assays

2008
[Lung cancer: an update in 2010].
    Bulletin du cancer, 2010, Volume: 97, Issue:1

    Topics: Angiogenesis Inhibitors; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Bevacizumab; Brain Neoplasms; Carcinoma, Non-Small-Cell Lung; Combined Modality Therapy; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lung Neoplasms; Quinazolines; Small Cell Lung Carcinoma

2010
Dual inhibition of EGFR and mTOR pathways in small cell lung cancer.
    British journal of cancer, 2010, Aug-24, Volume: 103, Issue:5

    Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Cells, Cultured; ErbB Receptors; Erlotinib Hydrochloride; Everolimus; Female; Humans; Intracellular Signaling Peptides and Proteins; Lung Neoplasms; Male; Middle Aged; Protein Serine-Threonine Kinases; Quinazolines; Signal Transduction; Sirolimus; Small Cell Lung Carcinoma; TOR Serine-Threonine Kinases; Xenopus Proteins

2010
[A case of Henoch-Schönlein purpura which was difficult to distinguish from a skin rash associated with gefitinib].
    Nihon Kokyuki Gakkai zasshi = the journal of the Japanese Respiratory Society, 2010, Volume: 48, Issue:7

    Topics: Antineoplastic Agents; Diagnosis, Differential; Exanthema; Female; Gefitinib; Humans; IgA Vasculitis; Lung Neoplasms; Middle Aged; Paraneoplastic Syndromes; Quinazolines; Small Cell Lung Carcinoma

2010
Radiosynthesis and initial in vitro evaluation of [18F]F-PEG6-IPQA--a novel PET radiotracer for imaging EGFR expression-activity in lung carcinomas.
    Molecular imaging and biology, 2011, Volume: 13, Issue:5

    Topics: Cell Line, Tumor; Chromatography, High Pressure Liquid; ErbB Receptors; Fluorine Radioisotopes; Humans; In Vitro Techniques; Lung Neoplasms; Positron-Emission Tomography; Quinazolines; Small Cell Lung Carcinoma

2011
Lung cancer: recent advances.
    Annals of the Academy of Medicine, Singapore, 2010, Volume: 39, Issue:11

    Topics: Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Global Health; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2010
Is FISH floating or still swimming in the lung cancer ocean?
    Annals of oncology : official journal of the European Society for Medical Oncology, 2011, Volume: 22, Issue:3

    Topics: Antineoplastic Agents; Biomarkers, Tumor; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Humans; In Situ Hybridization, Fluorescence; Lung Neoplasms; Meta-Analysis as Topic; Molecular Diagnostic Techniques; Mutation; Quinazolines; Small Cell Lung Carcinoma; Treatment Outcome

2011
Lung cancer signatures in plasma based on proteome profiling of mouse tumor models.
    Cancer cell, 2011, Sep-13, Volume: 20, Issue:3

    Topics: Adenocarcinoma; Adenocarcinoma of Lung; Adult; Aged; Aged, 80 and over; Animals; Antineoplastic Agents; Biomarkers, Tumor; Blood Proteins; Cell Line, Tumor; Enzyme-Linked Immunosorbent Assay; ErbB Receptors; Erlotinib Hydrochloride; Female; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Lung Neoplasms; Male; Mass Spectrometry; Mice; Middle Aged; Molecular Sequence Data; Neuroendocrine Cells; Nuclear Proteins; Proteins; Proteome; Proteomics; Quinazolines; RNA Interference; RNA, Small Interfering; Small Cell Lung Carcinoma; Thyroid Nuclear Factor 1; Transcription Factors

2011
Small cell lung cancer with an epidermal growth factor receptor mutation in primary gefitinib-resistant adenocarcinoma of the lung.
    Acta oncologica (Stockholm, Sweden), 2012, Volume: 51, Issue:4

    Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Drug Resistance, Neoplasm; ErbB Receptors; Female; Gefitinib; Humans; Mutation; Prognosis; Quinazolines; Small Cell Lung Carcinoma

2012
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:2

    Topics: Adenocarcinoma; Antineoplastic Combined Chemotherapy Protocols; Azabicyclo Compounds; Biomarkers, Tumor; Clinical Trials, Phase II as Topic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Gene Expression Profiling; Humans; Immunoblotting; In Situ Hybridization, Fluorescence; Lung Neoplasms; Mutation; Neoplasm Staging; Oligonucleotide Array Sequence Analysis; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Tumor Cells, Cultured

2012
HER2 as therapeutic target for overcoming ATP-binding cassette transporter-mediated chemoresistance in small cell lung cancer.
    Molecular cancer therapeutics, 2012, Volume: 11, Issue:4

    Topics: Animals; Antineoplastic Agents; ATP-Binding Cassette Transporters; Cell Line, Tumor; Humans; Lapatinib; Lung Neoplasms; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Molecular Targeted Therapy; Quinazolines; Receptor, ErbB-2; Small Cell Lung Carcinoma; Transfection; Up-Regulation

2012
Secondary resistance to erlotinib: acquired T790M mutation and small-cell lung cancer transformation in the same patient.
    Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2012, Volume: 7, Issue:6

    Topics: Adult; Biopsy; Bronchoscopy; Cell Transformation, Neoplastic; Diagnosis, Differential; DNA Mutational Analysis; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Fatal Outcome; Female; Follow-Up Studies; Humans; Lung Neoplasms; Protein Kinase Inhibitors; Quinazolines; Sequence Deletion; Small Cell Lung Carcinoma; Tomography, X-Ray Computed

2012
A patient with simultaneously appearing adenocarcinoma and small-cell lung carcinoma harbouring an identical EGFR exon 19 mutation.
    Annals of oncology : official journal of the European Society for Medical Oncology, 2012, Volume: 23, Issue:12

    Topics: Adenocarcinoma; Adult; Antineoplastic Agents; Cisplatin; Deoxycytidine; Docetaxel; ErbB Receptors; Erlotinib Hydrochloride; Female; Gemcitabine; Humans; Lung Neoplasms; Mutation; Neoplasm Recurrence, Local; Quinazolines; Small Cell Lung Carcinoma; Taxoids

2012
Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Lung cancer (Amsterdam, Netherlands), 2013, Volume: 80, Issue:1

    Topics: Adenocarcinoma; Carcinoma, Neuroendocrine; Cell Transformation, Neoplastic; Drug Resistance, Neoplasm; ErbB Receptors; Erlotinib Hydrochloride; Female; Humans; Immunohistochemistry; Lung Neoplasms; Middle Aged; Mutation; Neoplasm Grading; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma

2013
Tumor burden is predictive of survival in patients with non-small-cell lung cancer and with activating epidermal growth factor receptor mutations who receive gefitinib.
    Clinical lung cancer, 2013, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; DNA, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gefitinib; Humans; Lung Neoplasms; Lymphatic Metastasis; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Staging; Polymerase Chain Reaction; Prognosis; Protein Kinase Inhibitors; Quinazolines; Small Cell Lung Carcinoma; Survival Rate; Tumor Burden

2013
Treatment monitoring program for implementation of adherence to second-line erlotinib for advanced non-small-cell lung cancer.
    Clinical lung cancer, 2013, Volume: 14, Issue:4

    Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Aged, 80 and over; Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Drug Monitoring; Erlotinib Hydrochloride; Female; Follow-Up Studies; Health Plan Implementation; Humans; Lung Neoplasms; Male; Medication Adherence; Middle Aged; Neoplasm Staging; Patient Compliance; Prognosis; Protein Kinase Inhibitors; Quinazolines; Retrospective Studies; Salvage Therapy; Small Cell Lung Carcinoma; Survival Rate

2013